Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Jeffrey V Matous, Niels W.C.J. van de Donk, Albert Oriol, Alfred L. Garfall, Paula Rodríguez-Otero, Thomas Chalopin, Laura Rosinol Dachs, Katarina Uttervall, Maria- Victoria Mateos, Danielle Trancucci, Natalia Quijano Cardé, Caroline Hodin, Tara Stephenson, Athena Zuppa, Katherine Chastain, Lionel Karlin
Institutions: Colorado Blood Cancer Institute, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, University of Pennsylvania, Clinica Universidad de Navarra, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Karolinska University Hospital, Centro de Investigación del Cáncer, Janssen Research & Development (United States), Janssen (Belgium), Hôpital Lyon Sud
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038901